AUTHORS
Diana Zamora Quintanilla, MD, Jatin Thukral, MD2, Kanishka Uttam Chandani, M.B.B.S.3, Usman Ilyas, MD4, Amitkumar Mehta, MD5, Mazie Tsang, MD, MAS, MS6, Allison C Rosenthal, DO7, Talal Hilal, MD8
AFFILIATIONS
1 Mayo Clinic Arizona, Phoenix, Arizona, United States
2 NYMC/Landmark Medical Center, Rhode Island, United States
3 Mayo Clinic Arizona, Phoenix, Arizona, United States
4 Mayo Clinic Arizona, Phoenix, Arizona, United States
5 Mayo Clinic Arizona, Phoenix, Arizona, United States
6 Mayo Clinic Arizona, Phoenix, Arizona, United States
7 Mayo Clinic Arizona, Phoenix, Arizona, United States
8 Mayo Clinic Arizona, Phoenix, Arizona, United States
ABSTRACT
Background: BV-CHP has become the standard frontline regimen for CD30+ peripheral T-cell lymphoma (PTCL) based on the ECHELON-2 trial. However, because ~70% enrolled participants had anaplastic large cell lymphoma (ALCL), comparative survival outcomes in non-ALCL PTCL histologies remain poorly characterized. Although the phase II SGN35-032 study demonstrated promising activity of frontline BV-CHP in non-ALCL PTCL with CD30 <10%, comparative survival data remain limited due to underrepresentation of several PTCL histologies. We conducted a real-world analysis to evaluate histology-specific survival following BV-CHP vs. CHOP.
Methods: We performed a retrospective study using the TriNetX database. TriNetX is a multicenter-federated database of de-identified electronic health records from over 240 healthcare institutions. Adults (≥18 years) with PTCL who were treated with BV-CHP or CHOP were identified. Patients were identified between January 1, 2004, and June 30, 2026. Independent 1:1 propensity score matching was performed to balance baseline demographic and clinical characteristics, including age, sex, race, ethnicity, and comorbidities. Histologies with insufficient sample sizes were excluded from subgroup analyses. Stratification by CD30 status could not be performed due to database limitations. Overall survival (OS) was assessed at 1, 3, and 5 years by Kaplan-Meier estimates, log-rank tests, and univariable Cox proportional hazards models.
Results: Survival analyses were performed for the overall PTCL cohort (N=1240) and individual histologic subtypes with sufficient sample sizes, i.e., PTCL-NOS (n=724), AITL (n=200), ATLL (n=284), ALK+ ALCL (n=350), and ALK− ALCL (n=390). In the overall PTCL cohort (N=1240), the median age was 62 years, 61.9% were male, and 67.4% were non-Hispanic White. This cohort demonstrated improved OS with BV-CHP compared with CHOP, consistent with the survival benefit observed in ECHELON-2, with a 1-year OS of 77.3% versus 67.3% (HR 0.632, 95% CI 0.504–0.791; p<0.001), 3-year OS of 65.5% versus 54.6% (HR 0.664, 95% CI 0.547–0.805; p<0.001), and 5-year OS of 61.7% versus 49.9% (HR 0.67, 95% CI 0.55-0.81; p<0.001) for BV-CHP vs. CHOP, respectively. PTCL-NOS demonstrated a consistent and durable survival advantage favoring BV-CHP across all follow-up periods. One-year OS was 73.3% versus 63.5% (HR 0.65, 95% CI 0.49-0.85; p=0.002), 3-year OS was 59.6% versus 49.5% (HR 0.69, 95% CI 0.54-0.87; p=0.002), and 5-year OS was 54.8% versus 45.5% (HR 0.70, 95% CI 0.56-0.88; p=0.002). Similar survival benefits were observed in ALK+ ALCL with BV-CHP. 1-year OS was 88.5% versus 76.9% (HR 0.48, 95% CI 0.27-0.82; p=0.007), 3-year OS was 82.3% versus 72.1% (HR 0.56, 95% CI 0.35-0.91; p=0.018), and 5-year OS was 81.0% versus 70.5% (HR 0.57, 95% CI 0.35-0.91; p=0.018). In ALK− ALCL, BV-CHP was associated with improved 1-year OS at 81.7% versus 72.8% (HR 0.621, 95% CI 0.401-0.962; p=0.031) but not at 3- (72.4% versus 67.4%; HR 0.746, 95% CI 0.504–1.102; p=0.139) or 5-years (70.7% versus 64.4%; HR 0.729, 95% CI 0.497-1.070; p=0.105) for BV-CHP versus CHOP respectively. Although hazard ratios consistently favored BV-CHP in AITL and ATLL, no statistically significant improvement in OS was observed at 1, 3, or 5 years. In AITL, 1-, 3-, and 5-year OS was 71.9% versus 70.5% (HR 0.84, 95% CI 0.49-1.45; p=0.537), 58.4% versus 59.8% (HR 0.97, 95% CI 0.61-1.57; p=0.915), and 58.4% versus 54.0% (HR 0.92, 95% CI 0.58-1.47; p=0.723), respectively. Similarly, in ATLL, 1-, 3-, and 5-year OS was 64.2% versus 61.2% (HR 0.88, 95% CI 0.59-1.30; p=0.509), 47.2% versus 49.9% (HR 0.99, 95% CI 0.70–1.40; p=0.963), and 44.6% versus 44.9% (HR 0.98, 95% CI 0.70-1.38; p=0.898), respectively.
Conclusions: In this large real-world analysis, BV-CHP was associated with improved OS compared with CHOP in the overall PTCL cohort, PTCL-NOS, and ALK+ ALCL as a histologic subtype. The lack of a significant survival advantage in AITL and ATLL should be interpreted in the context of lower sample sizes, possible histologic misclassification, and limitations of retrospective large-database studies. However, this also suggests that BV-CHP activity may depend on PTCL biology. These findings extend the evidence supporting BV-CHP beyond ALCL and provide comparative effectiveness data for PTCL-NOS. Future studies should also evaluate subsequent therapies and hematopoietic stem cell transplantation.
DISCLOSURES
Diana Zamora Quintanilla, MD: No relevant conflicts of interest to declare.